CD8A and neoplasm: Our analysis focused on CD8+ T cells obtained from both pre-therapy (n = 19) and post-therapy (n = 29) tumor lesions from responder (n = 17) and non-responder (n = 31) patients (SI Appendix, Fig. S3 A and B).